10-Q: Crescent Biopharma Reports Q3 2025 Losses, Advances Oncology Pipeline

Crescent Biopharma, a preclinical-stage biotechnology company, reported significant operating losses for Q3 2025 while advancing its lead oncology programs CR-001, CR-002, and CR-003.

Summary

• Incurred a net loss of $24.6 million for the three months ended September 30, 2025, and $61.5 million for the nine months ended September 30, 2025.
• Reported an accumulated deficit of $79.4 million as of September 30, 2025.
• Held cash and cash equivalents totaling $133.3 million as of September 30, 2025.
• Used $44.8 million in net cash for operating activities during the nine months ended September 30, 2025.
• Completed a reverse recapitalization and merger with GlycoMimetics, Inc. on June 13, 2025, with Pre-Merger Crescent identified as the accounting acquirer.
• Raised approximately $142.3 million in net proceeds from a Pre-Closing Financing in June 2025, supplemented by $1.3 million in cash acquired from GlycoMimetics.
• Lead program CR-001, an anti-PD-1/anti-VEGF bispecific antibody, is progressing towards an Investigational New Drug (IND) application submission to the FDA in Q4 2025, with initial clinical data anticipated in H2 2026.
• Exercised the option for CR-002 in September 2025 and entered into a license agreement in November 2025, with an IND submission expected in mid-2026.
• CR-003, an investigational antibody drug conjugate, is also in preclinical development, with the option not yet exercised.
• Management anticipates that existing cash will be sufficient to fund operating plans for at least twelve months from the filing date of November 6, 2025.

Sentiment

Score: 6

Explanation: While the company continues to incur significant losses, typical for a preclinical biotech, it has a strong cash position ($133.3 million) following a substantial capital raise. Key programs (CR-001, CR-002) are advancing towards clinical trials with clear timelines (IND submissions in Q4 2025 and mid-2026, initial clinical data H2 2026). The strategic focus on bispecific antibodies mimicking a clinically validated mechanism (ivonescimab) provides a clear development path. However, the early stage of development, high burn rate, and inherent risks of drug development temper enthusiasm. The related party influence on governance is also a minor concern.

Positives

• Maintained a strong cash and cash equivalents balance of $133.3 million as of September 30, 2025, following a substantial $142.3 million net capital raise.
• Advanced the lead program CR-001 towards an Investigational New Drug (IND) application submission in Q4 2025, with initial clinical data expected in H2 2026.
• Successfully exercised the option and entered into a license agreement for CR-002 in November 2025, with an IND submission expected in mid-2026.
• CR-001 is strategically designed to replicate the functional properties of ivonescimab, which demonstrated significantly improved progression-free survival against Keytruda in a Phase 3 clinical trial.
• The company is pursuing a diversified portfolio approach with CR-002 and CR-003 targeting validated oncology pathways.
• Management projects that current cash resources are sufficient to fund operations for at least 12 months from the filing date.

Negatives

• Reported significant net losses of $24.6 million for Q3 2025 and $61.5 million for the nine months ended September 30, 2025.
• Accumulated a deficit of $79.4 million as of September 30, 2025, reflecting ongoing operational losses.
• Operates as a preclinical-stage biotechnology company with no products approved for commercial sale and no revenue generated from product sales to date.
• Anticipates incurring substantial losses for the foreseeable future, with profitability dependent on successful product development and commercialization.
• Substantially dependent on the success of its lead program, CR-001, with no guarantee that clinical trials will yield similar results to ivonescimab or be successfully completed.
• Relies heavily on third-party manufacturers and contract research organizations (CROs), introducing supply chain, quality control, and compliance risks.
• Fairmount Healthcare Fund II L.P., a related party, is the sole holder of Series A Preferred Shares and exerts significant influence over the board of directors, holding 60% of total board votes.

Risks

• The company is a preclinical-stage biotechnology company with a limited operating history, no completed clinical trials, and no products approved for commercial sale, making business assessment difficult.
• Has historically incurred and anticipates continuing to incur significant losses for the foreseeable future, and may never achieve profitability.
• May not be able to raise the substantial additional capital needed to support business plans, which could lead to dilution, operational restrictions, or relinquishing rights to technologies or product candidates.
• Drug development, including obtaining and maintaining regulatory approval, is costly, time-consuming, highly uncertain, and may not be successful.
• Substantially dependent on the success of its lead program, CR-001, and anticipated clinical trials may not be successful or produce comparable results to ivonescimab.
• May not be able to meet requirements for the chemistry, manufacturing, and control of its programs, potentially delaying or preventing product approval.
• Faces intense competition from multinational biopharmaceutical companies, specialized biotechnology companies, and academic institutions with significantly greater resources and expertise.
• The United States Food and Drug Administration (FDA) and comparable foreign regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, potentially delaying or preventing regulatory approvals.
• Disruptions at the FDA and other government agencies (e.g., funding shortages, personnel changes) could negatively affect the review of regulatory submissions.
• Even if regulatory approval is obtained, the company will be subject to extensive ongoing regulatory obligations and review, which may result in significant additional expense and penalties for non-compliance.
• May fail to achieve projected development goals in announced timeframes, leading to delays in commercialization and increased expenses.
• Does not currently own any issued patents, and a substantial part of its patent portfolio is in-licensed, making the ability to obtain and protect patent rights uncertain.
• May fail in obtaining or maintaining necessary rights to its programs through acquisitions and in-licenses.
• May be subject to patent infringement claims or may need to file such claims, resulting in substantial costs and liability.
• Patent protection could be reduced or eliminated due to changes to patent laws or non-compliance with legal requirements.
• May fail to identify or correctly interpret relevant third-party patents, adversely affecting the ability to develop and market products.
• May become subject to claims challenging the inventorship or ownership of its intellectual property.
• Patent terms may be inadequate to protect the competitive position of product candidates for an adequate amount of time.
• Technology licensed from third parties, including Paragon, may be subject to retained rights, potentially allowing competitors access to similar technologies.
• Expects to rely on agreements with third parties (CROs, CMOs) to develop product candidates; if these third parties fail to carry out contractual duties or meet deadlines, development could be delayed or halted.
• Business is dependent on key personnel, and inability to recruit and retain highly qualified personnel would be harmful.
• May experience difficulties in managing growth as the organization expands.
• Estimates of market opportunity and forecasts of market growth may prove inaccurate, and business may not grow at similar rates even if markets grow.
• Significant disruptions of information technology systems or breaches of data security could adversely affect the business.
• Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations, and standards may adversely affect the business.
• May become exposed to costly and damaging liability claims, and product liability insurance may not cover all damages.
• Business could be adversely affected by macroeconomic conditions, including economic downturns, inflation, interest rate increases, tariffs, and geopolitical events.
• Does not anticipate paying any dividends in the foreseeable future.
• Future sales of shares by existing shareholders could cause the share price to decline.
• Future sales and issuances of equity and debt could result in additional dilution to shareholders and cause the share price to decline.
• Preferred directors elected by holders of Series A Preferred Shares (an affiliate of Fairmount) have the ability to control or significantly influence all matters submitted to the board of directors for approval, representing 60% of total board votes.
• The company is governed by Cayman Islands law, and certain provisions of its Articles of Association have anti-takeover implications.
• The Articles of Association designate the courts of the Cayman Islands as the sole and exclusive forum for certain shareholder actions, potentially limiting shareholders' ability to obtain a favorable judicial forum.
• Ability to use Net Operating Loss (NOL) carryforwards and other tax attributes may be limited, including as a result of the Merger and Section 382 of the Internal Revenue Code.

Future Outlook

The company expects to continue incurring substantial losses for the foreseeable future as it advances its product candidates through preclinical and clinical development. Profitability is contingent upon successful development, regulatory approval, and commercialization of its product candidates, along with achieving sufficient revenues to cover its cost structure. Management anticipates submitting an Investigational New Drug (IND) application for CR-001 in Q4 2025, with initial clinical data expected in H2 2026, and an IND for CR-002 in mid-2026. The company will need to secure additional financing in the future to fund further research and development and eventual commercialization.

Management Comments

• "We believe CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab, marketed by Merck as Keytruda, the best-selling drug in the world and approved for the treatment of numerous cancers."
• "We believe the emerging data from the clinical development of ivonescimab supports the rationale for developing CR-001 in light of CR-001 and ivonescimab sharing the same proposed mechanism of action."
• "We plan to seek regulatory approvals for CR-001 to treat multiple solid tumor indications, both as a monotherapy and in combination with other mechanisms of action."
• "We expect that our existing cash will be sufficient to fund our operating plans for at least twelve months from the date of filing of this Quarterly Report."
• "We expect to continue to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development, approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure."

Industry Context

The company operates in the highly competitive and capital-intensive biotechnology sector, specifically targeting solid tumors within oncology. Its lead program, CR-001, is an anti-PD-1/anti-VEGF bispecific antibody, a class of immunotherapy gaining traction with assets like ivonescimab showing promise against established treatments such as Keytruda. The company's strategy aligns with industry trends towards multi-targeted therapies and antibody-drug conjugates (ADCs) to address unmet needs in cancer. However, as a preclinical-stage entity, it faces significant challenges from larger, more established pharmaceutical companies with extensive resources and approved products. The reliance on contract research and manufacturing organizations (CROs/CMOs), including WuXi Biologics, is standard for early-stage biotechs but also exposes the company to geopolitical risks, such as potential U.S. legislation like the BIOSECURE Act, which could impact supply chains and costs.

Comparison to Industry Standards

• CR-001 is designed to recapitulate the functional properties of ivonescimab, a bispecific anti-PD-1/anti-VEGF antibody developed by Akeso Biopharma and Summit Therapeutics Inc., which demonstrated significantly improved progression-free survival in a Phase 3 trial (HARMONi-2) against pembrolizumab (Keytruda) in non-small cell lung cancer.
• The company aims to compete with market-leading PD-1 inhibitors such as Keytruda (Merck) and Opdivo (Bristol Myers Squibb), which are widely approved for various cancer indications, setting a high bar for efficacy and safety.
• As a preclinical-stage company, its financial profile, characterized by significant operating losses and reliance on capital raises, is typical for the biotechnology industry where substantial investment is required for drug discovery and development before product revenue generation.
• The cash position of $133.3 million, following a recent financing, provides a runway of at least 12 months, which is a common benchmark for liquidity management in early-stage biotech companies.

Management Changes

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company was not a party to any material legal proceedings or claims.
• The company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business.

Related Party Transactions

• Paragon Therapeutics, Inc. and Parascent Holding LLC each beneficially own less than 5% of the company's share capital.
• Fairmount Funds Management LLC beneficially owns more than 5% of the company's capital, has two representatives (Peter Harwin, Jonathan Violin) appointed to the Board, and beneficially owns more than 5% of Paragon.
• Fairmount appointed Paragon's board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.
• In September 2024, Pre-Merger Crescent issued and sold 20,000,000 shares of Series Seed Convertible Preferred Stock to Fairmount Healthcare Fund II L.P. (an affiliate fund of Fairmount) for gross proceeds of $4.0 million.
• The Convertible Notes issued in October 2024 included an initial principal amount of $15.0 million from a related party (Fairmount, through an affiliate fund).
• Accrued research and development with Paragon amounted to $6,184,000 as of September 30, 2025, and $6,901,000 as of December 31, 2024.
• Accrued general and administrative expenses with Paragon were $89,000 as of September 30, 2025, and $320,000 as of December 31, 2024.
• Total related party accounts payable and other current liabilities were $6,273,000 as of September 30, 2025, and $7,221,000 as of December 31, 2024.
• Research and development expenses related to Paragon services were $6,175,000 for the three months ended September 30, 2025, and $21,244,000 for the nine months ended September 30, 2025.
• General and administrative expenses related to Paragon services were $89,000 for the three months ended September 30, 2025, and $719,000 for the nine months ended September 30, 2025.
• Non-cash interest expense related to related party convertible notes was $865,000 for the nine months ended September 30, 2025.
• Under the Parascent Warrant Obligation, warrants to purchase an aggregate number of shares equal to 1.00% of the company's outstanding ordinary shares (fully diluted) are to be granted on December 31, 2025, and December 31, 2026. The estimated fair value of warrants to be granted on December 31, 2025, was $2.6 million as of September 30, 2025.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and a decline in share price from future sales by existing shareholders. The significant influence of Series A Preferred shareholders (Fairmount affiliate) on corporate governance could impact decision-making. Long-term value creation is contingent on successful product development, but no dividends are anticipated in the foreseeable future.
• Employees are impacted by the company's growth plans, with expected increases in headcount and the scope of operations. Share-based compensation plans are in place to attract and retain talent, but job security is tied to the company's ability to secure future funding and advance its programs.
• Future customers (patients) stand to benefit from the potential development of novel therapies for solid tumors (CR-001, CR-002, CR-003) that aim to offer improved efficacy and safety over existing treatments.
• Suppliers and creditors, particularly third-party CROs and CMOs like WuXi Biologics and Paragon, are critical to the company's operations. Their business is tied to the company's development progress, but they also face risks related to geopolitical instability and trade restrictions.
• Regulatory bodies (e.g., FDA) are key stakeholders as the company's success depends on navigating extensive and unpredictable regulatory approval processes and maintaining compliance with various laws and regulations.

Next Steps

• Submit an Investigational New Drug (IND) application to the FDA for CR-001 in Q4 2025.
• Anticipate initial clinical data for CR-001 in the second half of 2026.
• Submit an IND for CR-002 in mid-2026.
• Continue to evaluate the full impact of the One Big Beautiful Bill Act (OBBBA) legislative changes as additional guidance becomes available.
• Grant Parascent warrants to purchase 1.00% of outstanding ordinary shares on a fully diluted basis on December 31, 2025, and December 31, 2026.
• Continue to evaluate additional opportunities to enhance capabilities and expand the development pipeline.

Key Dates

Recommendation

Crescent Biopharma is a preclinical-stage company with no revenue and significant losses, which is typical for its stage. The recent capital raise provides a solid cash runway for at least 12 months, crucial for advancing its oncology pipeline (CR-001, CR-002, CR-003) towards clinical trials. The strategic focus on bispecific antibodies mimicking a clinically validated mechanism (ivonescimab) offers a compelling rationale. However, the inherent high risks of drug development, including potential clinical trial failures, regulatory hurdles, and intense competition, warrant caution. The significant influence of a related party (Fairmount) on corporate governance, while disclosed, adds a layer of complexity. Investors should hold, awaiting further clinical data and progress in the pipeline, as the current stage is highly speculative but has clear near-term milestones.

Keywords

Biotechnology, Oncology, Solid Tumors, Bispecific Antibody, Antibody Drug Conjugates, Preclinical Development, Clinical Trials, Drug Development, SEC Filing, 10-Q, CR-001, CR-002, CR-003, PD-1, VEGF, Cancer Therapy, Pharmaceutical, NASDAQ, Reverse Recapitalization, Capital Raise, Fairmount, Paragon Therapeutics, WuXi Biologics